Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459338 · ClinicalTrials.gov registry record · Phase 3
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
A Phase 3 study of Healthy, sponsored by Adrian Vella.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04459338: Completed Phase 3 study of Healthy, sponsored by Adrian Vella.
NCT04459338 is a Phase 3 study of Healthy that has completed, run by Adrian Vella. The registered enrollment target is 11 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04459338, a Phase 3 study of Healthy, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study is to evaluate the role of GLP1R in the response to elevated glucagon concentrations.
Primary Outcome
This is the area under the curve for insulin secretion over the duration of the hyperglycemic clamp (0 to 300 minutes during the study in the Clinical Research Unit).
Conditions Studied
Interventions
- OTHER Saline
- BIOLOGICAL Exendin-9,39
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2022-06-14 |
| Phase | Phase 3 |
What the finished NCT04459338 record still lists
NCT04459338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT04459338 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04459338 about?
NCT04459338 is a clinical study titled "A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion". The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study is to evaluate the role of GLP1R in the response to elevated glucagon c...
What is the current status of trial NCT04459338?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2021-03-04. Estimated completion is 2022-06-14.
What conditions does trial NCT04459338 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04459338?
The interventions under investigation include: Saline (OTHER), Exendin-9,39 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04459338?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04459338 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04459338's enrollment target sits among peer trials
11 1031st of 1090 higher than 57 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
RECRUITING · Phase 3
-
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
RECRUITING · Phase 3
-
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
COMPLETED · Phase 3
-
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
COMPLETED · Phase 3
-
Study to Investigate the Potential of Probiotics in Yogurt
COMPLETED · Phase 3
-
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI